Recruiting
Disitamab Vedotin (RC48-ADC) in Breast Cancer
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
ClinicalTrials.gov IDNCT05851677
PhaseNot Applicable
Enrollment45
SponsorRenJi Hospital
AgeNo minimum reported
SexALL
Conditions studied
Breast Cancer
About this study
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Interventions
- Drug: Disitamab vedotin — recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Primary outcomes
- Progression-Free Survival (From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years))
Eligibility information
Inclusion Criteria:
* Histologically confirmed breast cancer;
* Prior or current use of Disitamab vedotin (RC48-ADC);
Exclusion Criteria:
* Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Study locations
- Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.